mAbxience announces European Commission approval of denosumab biosimilarsadriana.polo2025-07-02T15:00:56+02:00July 2, 2025|Press releases|
mAbxience and Corapharm Announce Strategic Licensing Agreement for Biosimilar Candidate in Southeast EuropeMiguel Martínez-Cava2025-07-02T12:29:30+02:00June 2, 2025|Press releases|
mAbxience and Abiogen Pharma Announce Strategic Licensing Agreement for Biosimilar Candidate in ItalyMiguel Martínez-Cava2025-07-02T12:28:58+02:00May 26, 2025|Press releases|
What does a company have in common with a cell?adriana.polo2025-11-12T12:02:38+01:00November 12, 2025|News|
Can AI optimizations impact every stage of a biologic production process?Bruno Martín2025-09-03T15:57:35+02:00September 3, 2025|News|
The science behind trust: how biosimilars are developed, proven and delivered to patientsBruno Martín2025-07-28T13:03:51+02:00July 28, 2025|News|
